

## QIBA Dynamic Contrast-Enhanced (DCE) MRI Biomarker Committee (BC) Meeting

Monday, April 25, 2022, at 11 a.m. (CT)

### Draft Meeting Summary

#### In attendance

Caroline Chung, MD (Co-chair)

Hendrik Laue, PhD (Co-chair)

Michael Boss, PhD

Ararat Chakhoyan, PhD

Jiacho Liang, PhD

Lucas McCullum, MS

Nancy Obuchowski, PhD

#### RSNA staff

Susan Stanfa

#### Topics Discussed:

- Progress on BC internal review of public comments and corresponding DCE Profile edits

#### Action Items / Next Steps:

- [Public Comment Resolutions](#) continue to be incorporated into the [DCE-MRI BC Profile](#)
- Dr. Lavini to add a paragraph to 4.1 describing how the Profile user would determine that their sequences are capable of properly resolving the higher concentrations of their contrast agent
- Mr. McCullum to reach out to Joshua Young at MD Anderson CCing Dr. Chung
- Dr. Laue to reach out to Andrey Fedorov, PhD, member of the [OSIPI Task Force 1.2: DCE/DSC software inventory](#)
  - The inventory being developed will list available tools and provide information to help users select a suitable software for perfusion imaging
  - Dr. Laue to determine whether the OSIPI challenge can be referenced in the Profile
- Dr. Boss to reach out to Drs. Bell, O'Connor, and Schmainda to schedule a meeting during ISMRM to discuss test-retest data
- The DCE-MRI BC is using an older Profile format with checklists arranged by imaging protocol and containing an actor column
  - In the new Profile template, checklists are arranged by actor in the front of the document, e.g., 3.6 Physicist Checklist, 3.7 Technologist/Scanner Operator Checklist, etc.
  - While the Process Cmte will not require BCs to adopt the new Profile template for existing Profiles, there are intermediary steps that can be taken to streamline some aspects of these older document formats
  - The 3.6.2 Specification table contains the same actor for every parameter, and Dr. Boss confirmed that it is acceptable to delete the actor column and add, "Actor: Physicist / Technologist" in a row above parameters
  - Dr. Boss recommended sending a screenshot of the table to Mr. O'Donnell, noting the DCE-MRI BC discussion
  - Dr. Boss stated that tables containing mixed actors can be left as is for now, as specifications will be edited and likely removed per [vetting requirements](#) developed by Process Cmte and future testing site feedback
- Dr. Liang introduced himself as having worked on the DCE-MRI Profile in the past and he has recently resumed his participation

**Next meeting:** Monday, May 9, 2022, at 11 a.m. (CT) [2<sup>nd</sup> & 4<sup>th</sup> Mondays of each month]

---

RSNA Staff attempt to capture the names of committee members participating on Zoom meetings. However, **if attendees join only by phone or do not use recognizable named, identification is not possible.** Participants are welcome to contact RSNA staff at [QIBA@RSNA.org](mailto:QIBA@RSNA.org) if their attendance is not reflected in meeting summaries.